Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Myovant Sciences Shares Rise on NDA Filing for Uterine Fibroid Combination Therapy Drug

Shares of Myovant Sciences traded 40% higher after the company reported that it has submitted a New Drug Application to the FDA for once-daily relugolix combination tablet for the treatment of women with uterine fibroids. Healthcare company Myovant Sciences Ltd. (...

Massive Reversal in Precious Metals but Fundamentals Improving

To underscore the volatility of this past week, consider the price action in Silver. Silver, days ago, had a chance to make its highest monthly close since October 2016. That is well over three years ago. Silver closed the week and the month at its lowest levels in six mon...

Analyst: Acquisition by Colorado-Based Specialty Pharma 'Could Bolster Revenue 400%'

The benefits and terms of the agreement are outlined in a Ladenburg Thalmann report. In a Sept. 18 research note, Ladenburg Thalmann analyst Jeffrey Cohen reported that Aytu BioScience Inc. (AYTU:NASDAQ) signed a definitive agreement to acquire Innovus Pharmaceutic...

Myovant Sciences Shares Up 110% on Phase 3 Advanced Prostate Cancer Data

Shares of Myovant Sciences opened 120% higher today after the firm reported a 97% response rate in its Phase 3 HERO Study of oral Relugolix in men with advanced prostate cancer. In the study, Relugolix achieved all six key secondary endpoints and the firm expects to submit a N...

Aytu Bio Shares Skyrocket After Gaining US Distribution Rights for Coronavirus Screening Test

Aytu BioScience shares rose by more than 750% at times today after the company reported that it secured an exclusive U.S. distribution agreement for COVID-19 point-of-care Rapid Test from a Hong Kong firm. Aytu BioScience Inc. (AYTU:NASDAQ) announced today...

Will Great Unlock Push Gold Prices Down?

As Great Lockdown was positive for the gold prices, the Great Unlock will be bad, right? We invite you to read our today’s article about the Great Unlock and find out whether it really must be negative for the gold prices. It’s all governme...

Revolutionizing Mental Health Treatment

(Click to play video.) Cybin Inc. ( NEO: CYBN , NYSE: CYBN , Forum ) is a Toronto-based life sciences company initially focused on psychedelic pharmaceutical therapies supporting research to advance psychedelic therapies centered on improving mental health and...

Will U.S. Shale Survive If Oil Hits $40?

Within a month, the U.S. oil benchmark West Texas Intermediate recorded two first-of-a-kind events. First, it fell below zero on April 20. Then, it soared up so high it is about to book its best month ever, CNBC's Pippa Stevens noted in a recent commentary. Still, many ...

From COVID to Nicotine Treatments, this Bio Stock is One to Watch

(Image via Lexaria Bioscience Corp.) There’s no shortage of excitement over potential COVID-19 vaccines. Just looking at the response to news around these developments is evidence of that, and one Company is working on a transformative, patented tech...

Buzz on the Bullboards: Today’s gainers and tomorrow’s winners

Investors dealt with another rate increase from the U.S. Federal Reserve, but could it be the finale for awhile? Time will tell, but many hope this, the 10th straight rate increase reaching its highest point in 16 years, will be enough to help calm unreasonably high ...
1 2 3 4 5 6 7 8 9 10 ...